BSX

SEC source: 0001225208-20-014095 · doc4.xml · nonDerivative · entry 1

Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,922

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-014094 · doc4.xml · derivative · entry 3

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 46,584 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant.

SEC source: 0001225208-20-014094 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,483

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $33.40 to $33.745, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-20-014094 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,067

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · balance_after: Includes 25,000 shares from grantor retained annuity trust that terminated on November 11, 2020.

SEC source: 0001225208-20-013294 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 662

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-013017 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960,421

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.12, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-20-012182 · doc4.xml · nonDerivative · entry 1

MACMILLAN STEPHEN P · CIK 0001239351 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

F1 · shares: Restricted stock granted in lieu of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $19,167, divided by the closing price of common stock on the date of grant. This grant represents the equivalent of two months of the board cash retainer as a result of board approval of the restoration of a portion of its cash compensation as disclosed on a Form 8-K dated October 5, 2020.

SEC source: 0001225208-20-012181 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,690

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-011472 · doc4.xml · derivative · entry 5

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 77,640 shares

Expires 2021-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant.

SEC source: 0001225208-20-011472 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,048

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.54 to $41.05, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-20-011472 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,688

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-011354 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,483

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-011201 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,972

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-011202 · doc4.xml · derivative · entry 5

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2020-10-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on October 25, 2011, the first anniversary of the date of grant.

SEC source: 0001225208-20-011202 · doc4.xml · nonDerivative · entry 3

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,622

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.70 to $41.05, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-20-011202 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-011096 · doc4.xml · derivative · entry 3

Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,851 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-20-011096 · doc4.xml · nonDerivative · entry 2

Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,993

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.44 to $40.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-011096 · doc4.xml · nonDerivative · entry 1

Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 266,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-21-000221 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,316

SEC source: 0001225208-20-011064 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,973

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.15 to $39.165, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-20-011063 · doc4.xml · nonDerivative · entry 1

Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,299

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $38.1812 to $39.24, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-011061 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,171

F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.06 to $39.0701, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-20-010897 · doc4.xml · nonDerivative · entry 1

Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,450

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-010203 · doc4.xml · derivative · entry 2

Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,930

Underlying: Common Stock · 32,930 shares

Expires 2030-08-03

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on August 3, 2021, the first anniversary of the date of grant.

SEC source: 0001225208-20-010203 · doc4.xml · derivative · entry 1

Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,894

Underlying: Common Stock · 7,894 shares

Expires 2024-08-03

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 3, 2021, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 3, 2021, the first anniversary of the date of grant.

SEC source: 0001225208-20-010202 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,016

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-009906 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,401

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-009667 · doc4.xml · derivative · entry 3

Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,185

Underlying: Common Stock · 728 shares

Expires 2023-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2020, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2020, the first anniversary of the date of grant.

SEC source: 0001225208-20-009667 · doc4.xml · nonDerivative · entry 2

Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,380

SEC source: 0001225208-20-009667 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,601

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-20-009668 · doc4.xml · derivative · entry 3

Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 855

Underlying: Common Stock · 854 shares

Expires 2021-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-20-009668 · doc4.xml · nonDerivative · entry 2

Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,269

SEC source: 0001225208-20-009668 · doc4.xml · nonDerivative · entry 1

Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,529

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-20-009579 · doc4.xml · derivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Interven Cardio

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,959

Underlying: Common Stock · 116,959 shares

Expires 2030-07-01

F1 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in one installment on January 1, 2023.

SEC source: 0001225208-20-008638 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,571

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-008565 · doc4.xml · derivative · entry 4

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,973

Underlying: Common Stock · 2,972 shares

Expires 2021-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017. the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017. the first anniversary of the date of grant.

SEC source: 0001225208-20-008565 · doc4.xml · nonDerivative · entry 3

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,195

F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-008565 · doc4.xml · nonDerivative · entry 2

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,164

SEC source: 0001225208-20-008565 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-20-008564 · doc4.xml · derivative · entry 4

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,762

Underlying: Common Stock · 1,761 shares

Expires 2021-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-20-008564 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,353

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-008564 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,106

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-20-011202 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,622

SEC source: 0001225208-20-007407 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,540

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-20-007408 · doc4.xml · nonDerivative · entry 1

ROUX DAVID J · CIK 0001234273 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,005

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-20-007406 · doc4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,043

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-20-007405 · doc4.xml · nonDerivative · entry 1

Sununu John E · CIK 0001458974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,155

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-20-007403 · doc4.xml · nonDerivative · entry 2

MACMILLAN STEPHEN P · CIK 0001239351 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,502

F2 · shares: Restricted stock granted in lieu of 100% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $57,500, divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-20-007403 · doc4.xml · nonDerivative · entry 1

MACMILLAN STEPHEN P · CIK 0001239351 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,948

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant.